{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Preoperative Flow Assessment in Coronary Artery Bypass Grafting"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "The study did not involve randomisation or blinding."
      },
      "Participants": {
        "score": 2,
        "evidence": "This observational nationwide cohort study included 18,211 patients who underwent first-time isolated CABG in Sweden from 2013 to 2020, identified from the SWEDEHEART registry."
      },
      "Intervention": {
        "score": 1,
        "evidence": "2,869 patients (15.8%) underwent preoperative flow assessment"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to assess the effect of preoperative physiological flow assessment on mid-term outcomes in patients undergoing coronary artery bypass grafting (CABG)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of all-cause mortality, stroke, new myocardial infarction, new coronary angiography, and new revascularization, measured over a median follow-up of 3.6 years."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "The study did not involve randomisation or blinding."
      },
      "Blinding": {
        "score": 0,
        "evidence": "The study did not involve randomisation or blinding."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "The study did not involve randomisation or blinding."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of the total cohort, 2,869 patients (15.8%) underwent preoperative flow assessment"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "preoperative flow assessment was associated with a higher risk of new angiography (adjusted hazard ratio [aHR] 1.32, 95% confidence interval [CI] 1.08\u20131.62, P = .008) and new revascularization (aHR 1.55, 95% CI 1.18\u20132.04, P = .002)"
      },
      "Harms": {
        "score": 0,
        "evidence": "There were no significant differences in mortality, post-discharge myocardial infarction, or stroke between groups."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not applicable."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 11,
    "max_score": 25
  },
  "model": "gpt-4o"
}